// App-Quantinova.ai

1005 : Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

Researchers

Presenter

  • Guy Heinrich Maria Jerusalem

Principal Investigators

  • Elena Kovalenko

  • Denise A. Yardley

  • Richard H. De Boer

  • Sara A. Hurvitz

  • Bent Ejlertsen

  • Sibel Blau

  • Mustafa Ozguroglu

  • Laszlo Landherr

  • Marianne Ewertz

  • Tanya Taran

  • Jenna Fan

  • Florence Noel-Baron

  • Anne-Laure Louveau

  • Howard A. Burris

Medical Centers

  • CHU Sart-Tilman Liege and Liege University, Liege, Belgium

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia

  • UCLA David Geffen School of Medicine, Los Angeles, CA

  • Copenhagen University Hospital, Copenhagen, Denmark

  • Rainier Hematology Oncology/NWMS, Seattle, WA

  • Istanbul University, Istanbul, Turkey

  • St. Laszlo Teaching Hospital, Budapest, Hungary

  • Department of Oncology, Odense University Hospital, Odense, Denmark

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharma, Paris, France

  • Novartis Pharma, Paris, France

  • Sarah Cannon Research Institute, Nashville, TN

Locations

  • Turkey

  • Australia

  • United States

  • France

  • Denmark

  • Belgium

  • Hungary

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Capecitabine

  • Everolimus

  • Exemestane

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • NCT01783444

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved